Your browser is no longer supported. Please, upgrade your browser.
NVO Novo Nordisk A/S daily Stock Chart
Novo Nordisk A/S
Index- P/E20.41 EPS (ttm)2.46 Insider Own26.40% Shs Outstand1.87B Perf Week2.83%
Market Cap93.77B Forward P/E19.35 EPS next Y2.60 Insider Trans0.00% Shs Float1.32B Perf Month12.22%
Income6.06B PEG2.62 EPS next Q0.64 Inst Own8.80% Short Float0.14% Perf Quarter3.16%
Sales17.25B P/S5.44 EPS this Y2.80% Inst Trans0.34% Short Ratio1.17 Perf Half Y-10.97%
Book/sh2.84 P/B17.68 EPS next Y3.55% ROA39.60% Target Price60.40 Perf Year16.28%
Cash/sh- P/C- EPS next 5Y7.80% ROE81.80% 52W Range41.03 - 58.37 Perf YTD-6.43%
Dividend1.28 P/FCF61.22 EPS past 5Y14.60% ROI74.60% 52W High-13.96% Beta0.66
Dividend %2.55% Quick Ratio0.80 Sales past 5Y7.40% Gross Margin84.00% 52W Low22.40% ATR0.66
Employees42688 Current Ratio1.10 Sales Q/Q-5.30% Oper. Margin43.50% RSI (14)67.75 Volatility0.96% 1.15%
OptionableYes Debt/Eq0.01 EPS Q/Q8.40% Profit Margin35.10% Rel Volume0.45 Prev Close50.14
ShortableYes LT Debt/Eq0.00 EarningsAug 09 BMO Payout288.30% Avg Volume1.63M Price50.22
Recom1.00 SMA205.72% SMA506.04% SMA2000.11% Volume732,900 Change0.16%
Dec-29-17Upgrade JP Morgan Underweight → Neutral
Dec-06-17Upgrade BofA/Merrill Neutral → Buy
Dec-01-17Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-25-17Downgrade Exane BNP Paribas Outperform → Neutral
Sep-06-17Upgrade BofA/Merrill Underperform → Neutral
Oct-31-16Downgrade DNB Markets Buy → Hold
Oct-31-16Downgrade Citigroup Buy → Neutral
Oct-28-16Downgrade BofA/Merrill Neutral → Underperform
Sep-23-16Initiated Piper Jaffray Neutral
Sep-13-16Upgrade Exane BNP Paribas Neutral → Outperform
Sep-09-16Downgrade JP Morgan Overweight → Neutral
Sep-01-16Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-31-16Upgrade HSBC Securities Reduce → Hold
Aug-08-16Downgrade BofA/Merrill Buy → Neutral
Aug-28-15Initiated Leerink Partners Mkt Perform $56
Jun-09-15Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-15-15Initiated Societe Generale Sell
May-28-13Upgrade Deutsche Bank Sell → Hold
Mar-31-10Initiated Deutsche Bank Hold
Mar-30-10Downgrade Mehta Partners Outperform → Market Perform
Jul-13-18 07:42AM  Novozymes and Novo Nordisk sign deal to source power from Denmarks largest wind farm CNBC
Jul-10-18 02:46PM  Drugmakers Cancel Price Hikes After California Law Takes Effect Bloomberg
Jul-06-18 12:59PM  Top Stocks Set to Disrupt the Diabetes Market Motley Fool
Jul-05-18 07:25AM  Free Technical Reports on Novavax and Three Additional Biotech Equities ACCESSWIRE
Jun-30-18 05:32PM  The Week Ahead In Biotech: Delayed Clinical Trial Releases In Focus Benzinga
Jun-26-18 07:00AM  EyePoint Pharmaceuticals Appoints Göran Ando, M.D., to Board of Directors GlobeNewswire
Jun-25-18 09:12AM  Novo Nordisk (NVO) Announces Results in Diabetes Studies Zacks
Jun-24-18 06:31AM  5 Biggest Blockbuster Diabetes Drugs of the Future Motley Fool
Jun-23-18 11:01AM  Novo Says Tresiba Shows Significantly Better Blood Sugar Control Bloomberg
10:00AM  Novo reveals more Ozempic data on change in body weight by baseline BMI Reuters
Jun-22-18 08:02PM  Drug Pricing Turns to Insulin as Politicians, AMA and Docs Look to Pharma
09:52AM  Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI Zacks
Jun-21-18 05:33PM  Novo Nordisk Stock Rises 4% Over 2 Sessions
03:39PM  Novo Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study Zacks
09:48AM  Novo Nordisk Stock Pops Nearly 3% on Positive Diabetes-Drug Results
Jun-20-18 05:51PM  Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs Zacks
09:30AM  LLY vs. NVO: Which Stock Should Value Investors Buy Now? Zacks
Jun-17-18 12:03PM  Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming Motley Fool
Jun-08-18 03:53AM  Novo Nordisk shares fall after report of layoffs Reuters
May-31-18 10:58AM  Top Diabetes Stocks to Buy Today Motley Fool
08:49AM  Emisphere Development Update GlobeNewswire
May-30-18 08:28AM  Novo Nordisk's Oral Ozempic Positive in Diabetes Study Zacks
May-29-18 12:54PM  Novo Nordisk's oral diabetes drug beats Jardiance in study Reuters
May-25-18 06:32PM  How to Invest in Diabetes Stocks Motley Fool
05:38AM  Almost a quarter of the worlds population will be obese by 2045 MarketWatch
May-23-18 01:39PM  Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs
May-22-18 08:00AM  Report: Developing Opportunities within El Pollo Loco, Chemed, Novo Nordisk A/S, FactSet Research, Fair Isaac, and HCP Future Expectations, Projections Moving into 2018 GlobeNewswire
May-18-18 10:56AM  Top Research Reports for Walmart, AT&T & Novo Nordisk Zacks
May-07-18 04:23PM  Novo Nordisk Fights Payer Pressure With New Meds Motley Fool
04:11PM  Is Novo Nordisk A/S (NYSE:NVO) A Buy At Its Current PE Ratio? Simply Wall St.
May-03-18 11:42AM  Novo Nordisk (NVO) Q1 2018 Earnings Conference Call Transcript Motley Fool
May-02-18 10:59AM  Novo Nordisk (NVO) Beats Q1 Earnings Estimates, Sales Miss Zacks
06:12AM  Drugmaker Novo Nordisk beats first quarter profit expectations, nudges up 2018 outlook Reuters
03:36AM  We have a policy of not taking list price increases of ab... CNBC Videos
02:37AM  [$$] Novo Nordisk shares climb as it lifts sales and profit Financial Times
Apr-27-18 02:43PM  Grifols, Novo expansions prompt $1.3M renovation of JoCo training center American City Business Journals
Apr-26-18 08:30AM  Emisphere Amends License Agreement with Novo Nordisk GlobeNewswire
Apr-18-18 03:02PM  Xultophy® approved in Canada for the treatment of adults with type 2 diabetes CNW Group
Apr-11-18 08:00AM  Novo Nordisk launches Rebinyn®, a new, long-acting treatment for patients with hemophilia B in Canada CNW Group
08:00AM  Novo Nordisk announces the availability of Zonovate® for the treatment of patients with hemophilia A in Quebec CNW Group
Apr-06-18 05:35PM  Novo Nordisk Obtains Licence for Sickle Cell Disease Program Zacks
Apr-05-18 09:42AM  Novo Nordisk buys blood drug licence to boost anaemic biopharma business Reuters
Apr-03-18 08:16AM  Status regarding Novo Nordisk's holding of its own shares (31 March 2018) GlobeNewswire
Mar-28-18 07:35AM  Market Trends Toward New Normal in Novo Nordisk A/S, Brookfield Asset Management, Dun & Bradstreet, Goldcorp, NorthStar Asset Management Group, and IMAX Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Mar-23-18 11:53AM  These 12 Drugs Launching In 2018 Are Headed For Blockbuster Status Investor's Business Daily
Mar-22-18 12:47PM  30 Most Obese Countries In The World in 2018: Biggest Anti-Obesity Drug Markets Insider Monkey
10:59AM  Drugmaker Novo Nordisk looks to former oil boss to energise M&A Reuters
Mar-21-18 09:59AM  Novo Nordisk Poised on Strong Pipeline Amid Competition Zacks
Mar-15-18 09:45AM  Diabetes Devices Market on a Tear: 3 Stocks for Solid Returns Zacks
Mar-05-18 08:00AM  OZEMPIC® now available for Canadians with type 2 diabetes PR Newswire
Mar-02-18 03:00AM  Novo Nordisk CEO Sees Competition in U.S. Driving Down Prices Bloomberg Video
03:00AM  Novo Nordisk CEO Sees Competition in U.S. Driving Down Prices Bloomberg
Feb-28-18 07:01AM  [$$] Novo to invest $165m in first superbug venture fund Financial Times
04:33AM  Novo Holdings launches $165 million 'superbug' drug venture fund Reuters
03:36AM  Novo Holdings launches $165 million 'superbug' drug venture fund Reuters
Feb-27-18 09:38AM  Pfizer Gets Mixed Feedback on Cancer Treatments From CHMP Zacks
Feb-23-18 09:11AM  Todays Biotech Movers: Sangamo Therapeutics, Inc. (NASDAQ:SGMO) And Novo Nordisk A/S (ADR) (NYSE:NVO) Market Exclusive
Feb-22-18 05:39AM  Novo Nordisk successfully kicks off final-stage trials for first diabetes pill Reuters
Feb-21-18 11:52AM  Novo Nordisk gets nod from U.S. drug purchaser for new diabetes hope Reuters
08:18AM  Eurozone Beats United States Again: 5 Hot Stock Picks Zacks
Feb-20-18 08:07AM  The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal Zacks
Feb-16-18 04:00PM  Top Research Reports for Novo Nordisk, TJX Companies & Cigna Zacks
Feb-14-18 08:55PM  5 More Stocks to Buy to Feed the Bear Motley Fool
11:14AM  FDA approves insulin dose calculator that's connected to a smartphone app CNBC
Feb-12-18 07:10AM  Blog Exposure - Novo Nordisks Ozempic is Approved in the EU for the Treatment of Type 2 Diabetes ACCESSWIRE
05:31AM  GlaxoSmithKline plc -- Moody's: M&A greatest downside risk to European pharma companies' credit quality in 2018 Moody's
Feb-06-18 04:30PM  Novo Nordisk's Dichotomy Abounds Motley Fool
10:19AM  FOCUS-In diabetes war, Novo Nordisk aims to break mould with new pill Reuters
Feb-05-18 02:32PM  Novo Nordisk plans $65M expansion in Johnston County American City Business Journals
08:14AM  Foreign Stock Roundup: RDS.A & AZN Impress, NVO & BABA Disappoint Zacks
07:20AM  Wired News Teva Pharma Announced the Acceptance of Fremanezumabs Marketing Authorization Application by EMA ACCESSWIRE
Feb-03-18 02:32PM  3 Top Obesity-Drug Stocks to Consider Buying Now Motley Fool
Feb-01-18 01:16PM  Novo Nordisk Is on High But Shaky Ground Bloomberg -6.54%
12:13PM  Germanys DAX ends sharply lower as global bond yields keep climbing MarketWatch
10:43AM  Novo Nordisk posts 4Q profit Associated Press
08:49AM  Novo Nordisk (NVO) Misses Q4 Earnings Estimates, Sales Beat Zacks
06:21AM  Novo Nordisk CEO welcomes Amazon, Berkshire, JPMorgan pharma company Reuters
05:22AM  Novo Nordisk CEO Is 'Quite Optimistic' About 2018 Growth Bloomberg Video
Jan-30-18 09:46AM  Company News For Jan 30, 2018 Zacks
09:21AM  Sanofi on a Buyout Spree This Month, to Buy Ablynx for $4.8B Zacks
08:52AM  Why Novo Nordisk (NVO) Might Surprise This Earnings Season Zacks
Jan-29-18 08:07PM  Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom Reuters
01:59PM  Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done
12:54PM  Sanofi Beats Out Novo Nordisk in Bid to Buy Ablynx
12:15PM  Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom Reuters
12:14PM  Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom Reuters
11:41AM  Sanofi Pays 112% Premium for Ablynx Bloomberg Video
10:59AM  France's Sanofi buys biotech company Ablynx for $4.8 billion Associated Press
10:20AM  Sanofi beats Novo to buy Ablynx for 3.9 billion euros in biotech M&A boom Reuters
08:46AM  Sanofi's $16 Billion Splurge Leaves Novo Behind on Blood Deals Bloomberg
08:04AM  INTERVIEW: Novo Nordisk remains on hunt for biopharma deals Reuters
07:52AM  Novo Nordisk remains on hunt for biopharma deals Reuters
02:39AM  Sanofi Leapfrogs Novo With $4.8 Billion Cash Bid for Ablynx Bloomberg
12:00AM  Born From Frozen Camel Blood, Ablynx Is $4.8 Billion Prize Bloomberg
Jan-23-18 09:03AM  Reading the Estimates for Novartiss Alcon in 4Q17 Market Realist
07:34AM  Whats Expected of Novartiss Sandoz Segment in 4Q17? Market Realist
Jan-22-18 11:30AM  Behind Novartiss 4Q17 Estimates: Innovative Medicines Market Realist
10:00AM  Behind Novartiss 4Q17 Earnings: Why Some Expect Revenue Growth Market Realist
Jan-19-18 08:43AM  The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis Zacks
Jan-18-18 12:33PM  Scoop Up Teva Pharmaceutical Industries Ltd (ADR) on Every Dip InvestorPlace
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. Novo Nordisk A/S has a research and licensing agreement with DUKE National University Singapore Medical School to develop stem cell-based treatments for chronic heart failure and age-related macular degeneration, as well as a research collaboration with Kallyope Inc. The company markets and distributes its products through distributors and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.